Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Merck KGaA builds presence in China
by Alex Scott
November 14, 2016
| A version of this story appeared in
Volume 94, Issue 45
Merck KGaA plans to spend $90 million on a facility in Nantong, China, that supplies pharmaceutical services and products such as high-purity inorganic salts and cell culture media. The firm just inaugurated a $200 million facility in Nantong for manufacturing pharmaceuticals on China’s Essential Drug List. Merck claims it is the first multinational to operate such a plant in China. The first of the drugs are set to be delivered to patients in the second half of 2017.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X